Camp4 Therapeutics Corp 8K

CAMP4 Therapeutics obtained Australian regulatory clearance to begin a Phase 1/2 trial of CMP-002 in SYNGAP1-related disorder, triggering eligibility for up to an additional $50 million in private placement proceeds under a prior securities purchase agreement.

CAMP4 Therapeutics Corporation announced that it has received regulatory clearance from Australia’s Therapeutic Goods Administration and a local Human Research Ethics Committee to initiate a Phase 1/2 first-in-human clinical trial of CMP-002 for SYNGAP1-related disorder, a milestone that also satisfies a condition under its September 9, 2025 Securities Purchase Agreement and makes the company eligible to receive up to an additional $50 million in gross proceeds through a second closing of a previously announced private placement expected to occur within five business days, subject to customary conditions. The clearance allows CAMP4 to open an Australian trial site, expected to be one of the initial enrollment locations, while the company advances additional global regulatory filings to expand the study internationally and support development of CMP-002 and its broader pipeline.

Filing Facts

CIK

1736730

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-049661

Alert Tier

7